Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Establishment of a Quality Control Standard System for Coronary Revascularization in Coronary Heart Disease Based on Dual Antiplatelet Therapy (DAPT)

NCT07354828 is registered in ClinicalTrials.gov with Shenyang Northern Hospital as lead sponsor.

NCT NCT07354828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07354828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Establishment of a Quality Control Standard System for Coronary Revascularization in Coronary Heart Disease Based on Dual Antiplatelet Therapy (DAPT)
Lead sponsor
Shenyang Northern Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
December 30, 2025
Completion date
June 30, 2029
Enrollment
3,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome (acs), coronary artery disease (cad), high bleeding risk (hbr)